公司概覽
業務類別 Biotechnology
業務概覽 Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediateddiseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
公司地址 201 Elliott Avenue West, Seattle, WA, USA, 98119
電話號碼 +1 206 676-5000
傳真號碼 +1 206 676-5005
公司網頁 https://www.omeros.com
員工數量 175
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Gregory A. Demopulos,M.D. Chairman of the Board, President and Chief Executive Officer 美元 972.53K 30/04/2026
Dr. George A. Gaitanaris, M.D.,PhD Vice President, Science and Chief Scientific Officer -- 31/03/2026
Dr. J. Whitaker, J.D.,M.D. Vice President, Clinical Development -- 31/03/2026
Mr. David J. Borges Vice President, Finance, Chief Accounting Officer, Principal Financial Officer and Treasurer 美元 325.60K 31/03/2026
Mr. Peter W. Williams Vice President, Human Resources -- 31/03/2026
Mr. David W. Ghesquiere Vice President and Chief Business Development Officer -- 31/03/2026
Ms. Nadia Dac Vice President and Chief Commercial Officer -- 31/03/2026
Dr. Mariana N. Dimitrova, PhD Vice President, Chemistry, Manufacturing and Controls -- 31/03/2026
Mr. Peter B. Cancelmo Vice President, General Counsel and Corporate Secretary 美元 489.48K 31/03/2026
Dr. Andreas Grauer, M.D. Vice President and Chief Medical Officer -- 31/03/2026
Dr. Catherine A. Melfi, PhD Vice President, Regulatory Affairs and Quality Systems and Chief Regulatory Officer -- 31/03/2026
 
董事會成員
董事會 職務 更新日期
Dr. Leroy E. Hood,M.D.,Ph. Independent Director 30/04/2026
Dr. Gregory A. Demopulos,M.D. Chairman of the Board, President and Chief Executive Officer 30/04/2026
Mr. Thomas J. Cable Lead Independent Director 30/04/2026
Dr. Peter A. Demopulos,M.D. Director 30/04/2026
Mr. Arnold C. Hanish Independent Director 30/04/2026
Dr. Thomas F. Bumol, PhD Independent Director 30/04/2026
Dr. Rajiv Shah, M.D. Independent Director 30/04/2026
Ms. Diana T. Perkinson Independent Director 30/04/2026
 
所屬ETF (更新日期: 02/05/2026 02:24)
代號 名稱 佔比% 持有日期
IWMiShares Russell 2000 ETF2.24%29/04/2026
XPHState Street® SPDR® S&P® PhrmctlsETF0.74%29/04/2026
IWOiShares Russell 2000 Growth ETF0.69%29/04/2026
SCHASchwab US Small-Cap ETF™0.48%29/04/2026
VTWOVanguard Russell 2000 ETF0.47%31/03/2026
VHTVanguard Health Care ETF0.29%31/03/2026
IHEiShares US Pharmaceuticals ETF0.26%29/04/2026
IWCiShares Micro-Cap ETF0.24%29/04/2026
ITOTiShares Core S&P Total US Stock Mkt ETF0.19%29/04/2026
PRFZInvesco RAFI US 1500 Small-Mid ETF0.17%29/04/2026
VFMOVanguard US Momentum Factor ETF0.14%31/03/2026
IWNiShares Russell 2000 Value ETF0.09%29/04/2026
VTWGVanguard Russell 2000 Growth ETF0.08%31/03/2026
SCHBSchwab US Broad Market ETF™0.07%29/04/2026
OPTZOptimize Strategy Index ETF0.05%29/04/2026
ONEQFidelity Nasdaq Composite ETF0.05%29/04/2026
BBCVirtus LifeSci Biotech Clinical Trls ETF0.04%29/04/2026
IWViShares Russell 3000 ETF0.03%29/04/2026
PILLDirexion Daily Phrmctcl&MdclBl3XShrsETF0.02%29/04/2026
QQQSInvesco NASDAQ Future Gen 200 ETF0.01%29/04/2026
 1    2  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.